Amir Danino, Innoventric – Studio Interview | LSI USA '25

Since its foundation, Innoventric has been committed to addressing the complexities of tricuspid regurgitation with our transcatheter TR solutions. As leaders in cross-caval technologies, we are dedicated to the ongoing development of advanced devices to extend the reach of TR treatment. Our approach is rigorously data-driven, with its roots grounded deep in clinical research. We possess a robust patent portfolio in cross-caval technologies and are devoted to continuous improvement to enhance patient care for those with structural heart disease.

LSI USA ‘26 is filling fast. Secure your spot today to join Medtech and Healthtech leaders.

March 16th - 20th, 2026  Waldorf Astoria, Monarch Beach Register arrow